040 – Biogen faces another headwind with Zolgensma approval

Hi all, I’m back today talking about the approval of Avexis/Novartis’ gene therapy for spinal muscular atrophy, Zolgensma. I also talk about how I came to a conclusion about whether or not I should short Biogen.

Follow me on twitter @matthewlepoire
*this is not investment advice*


Novartis buys Avexis!

-Novartis buys gene therapy company, Avexis for $8.7 billion

-Spark is another gene therapy company I like, involved in hemophilia and eye-related blindness diseases

Follow me on twitter @matthewlepoire

%d bloggers like this: